Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Janssen receives patent for central alpha2-adrenoceptor antagonists

Aug. 10, 2000

Vernalis designs potent inhibitors of lipid peroxidation and cell toxicity

Aug. 10, 2000

Onset of inherited neurodegenerative disorders attributed to random cell death

Aug. 10, 2000

CNS-reactive human MAbs promote remyelination in MS model

Aug. 9, 2000

Ginkgo biloba extract shows promise as treatment for dementia

Aug. 8, 2000

CRF1 receptor antagonist displays safety and efficacy in clinical trial

Aug. 8, 2000

Proteasome inhibitor PS-519 protective in cerebral ischemia model

Aug. 8, 2000

GABA-B antagonist CGP-36742 promnestic in epilepsy model

Aug. 8, 2000

PTSD indication sought for Paxil in Canada

Aug. 7, 2000

Reminyl receives FDA approvable letter

Aug. 7, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...